Lv2
150 积分 2025-11-19 加入
Safety of switching from lecanemab to donanemab in 20 consecutive patients with Alzheimer's disease
1个月前
已完结
Reducing ARIA risk in Alzheimer's disease: Real-world impact of APOE genotype-guided slow titration with aducanumab and lecanemab
1个月前
已完结
Biomarker-driven diagnosis of Alzheimer's disease: Toward precision neurology
1个月前
已关闭
A Japanese registry for optimizing the safe use of anti-amyloid therapies for Alzheimer’s disease in Japan
1个月前
已完结
An update on emerging anti-amyloid-β monoclonal antibodies for treating Alzheimer’s disease: the role of apolipoprotein E
1个月前
已完结
Are Australians living with dementia ready for new therapies?
1个月前
已完结
Donanemab for Alzheimer Disease—Who Benefits and Who Is Harmed?
1个月前
已完结
Amyloid-Targeting Monoclonal Antibodies for Alzheimer Disease
1个月前
已完结
Who Should—and Can—Get Lecanemab, the New Alzheimer Disease Drug?
1个月前
已完结
Conveying Risks of Harm in Alzheimer Disease by Amyloid Lowering
1个月前
已完结
皖公网安备34019202002308
